Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MELK | Q14680 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232872 | 0.82 | TAAR1 (0.40) | HTR2CHTR2BALDH1A1MELKFFAR1 | |
| SCHEMBL5633251 | 0.82 | ALDH1A1 (0.47) | HTR2CHTR2BALDH1A1MELKFFAR1 | |
| SCHEMBL241880 | 0.80 | CYP4F2 (0.53) | CYP4F2CYP4A11TBXA2RLTA4HEPHX2 | |
| SCHEMBL23720099 | 0.78 | CYP4F2 (0.42) | CYP4F2CYP4A11TBXA2RLTA4HEPHX2 | |
| SCHEMBL236362 | 0.77 | CYP4F2 (0.43) | CYP4F2CYP4A11TBXA2RLTA4HEPHX2 | |
| SCHEMBL3864906 | 0.77 | ASIC3 (0.38) | HTR2CHTR2BASIC3 | |
| SCHEMBL1244860 | 0.77 | FFAR1 (0.51) | ALDH1A1MELKFFAR1NOS1EGFR | |
| SCHEMBL232937 | 0.75 | HTR2C (0.47) | HTR2CHTR2BALDH1A1FFAR1ASIC3 | |
| SCHEMBL2180350 | 0.74 | HTR2C (0.51) | HTR2CHTR2BALDH1A1ASIC3EGFR | |
| SCHEMBL612967 | 0.74 | PTGES (0.47) | CYP4F2CYP4A11LTA4HEPHX2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023827-A1 | EMM-41 Composition, Methods of Making and Uses Thereof | EXXONMOBIL RES & ENG CO (US) | 2022-01-27 | — | — | US | disclosed |
| US-20190218106-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | EXXONMOBIL RES & ENG CO (US) | 2019-07-18 | — | — | US | disclosed |
| US-10252918-B2 | EMM-28, a novel synthetic crystalline material, its preparation and use | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170158521-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023827-A1 | EMM-41 Composition, Methods of Making and Uses Thereof | CD14, CD68, MASP2 | CYP4F2 3757/4885CYP4A11 3308/4885TBXA2R 3591/4885 |
| US-10252918-B2 | EMM-28, a novel synthetic crystalline material, its preparation and use | CD14, ERG28, DAP3 | CYP4F2 2148/4885CYP4A11 3171/4885TBXA2R 4396/4885 |
| US-20170158521-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | CD14, ERG28, DAP3 | CYP4F2 2148/4885CYP4A11 3171/4885TBXA2R 4396/4885 |
| US-20190218106-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | CD14, ERG28, DAP3 | CYP4F2 2148/4885CYP4A11 3171/4885TBXA2R 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.